Risk factors for progressive sarcopenia 6 months after complete resection of lung cancer: what can thoracic surgeons do against sarcopenia?
Lung cancer
chronic obstructive pulmonary disease (COPD)
gastric cancer
operation time
surgery
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
entrez:
11
4
2020
pubmed:
11
4
2020
medline:
11
4
2020
Statut:
ppublish
Résumé
Our previous report described how postoperative progression of sarcopenia predicted long-term prognosis after complete resection of non-small cell lung cancer (NSCLC) in heavy smokers. However, there are currently no effective means to treat progressive sarcopenia. In this study, we aimed to confirm our previous findings in a larger population and to identify factors associated with postoperative progression of sarcopenia to propose possible preventative measures. This retrospective study analyzed the data of 1,095 patients who underwent curative lobar resection for NSCLC at Kanagawa Cancer Center. We divided patients into four groups according to sex and Brinkman index (BI) above or below 600. Six-month postoperative changes in the skeletal muscle index (SMI) were calculated and associations between clinicopathological factors including changes in SMI and mortality from postoperative 6 months were examined. Only in groups in which postoperative depletion of SMI was shown to be associated with the prognosis, we identified clinicopathological factors associated with depletive SMI. The overall survival rates of 1,095 patients were 89.8% and 82.5% at 3 and 5 years, respectively. The median 6-month change in SMI was -3.4% (range, -22.3% to +17.9%). Multivariate analysis revealed that poor prognosis was independently predicted by a large reduction in the SMI (cut-off value: -10%) in males with a BI ≥600. In 391 heavy-smoking males, factors associated with a postoperative change in SMI ≤-10% were history of other cancers (including gastric cancer) low forced expiratory volume in one second (FEV 1.0, cut-off value: 1,870 mL), and prolonged operation time (cut-off value: 200 minutes). Perioperative measures to prevent postoperative sarcopenia are appropriate for heavy smokers. We obtained some clues regarding countermeasures, one of which may be avoiding long-time operation. Further studies including clinical trials to assess perioperative anti-sarcopenia treatments, are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Our previous report described how postoperative progression of sarcopenia predicted long-term prognosis after complete resection of non-small cell lung cancer (NSCLC) in heavy smokers. However, there are currently no effective means to treat progressive sarcopenia. In this study, we aimed to confirm our previous findings in a larger population and to identify factors associated with postoperative progression of sarcopenia to propose possible preventative measures.
METHODS
METHODS
This retrospective study analyzed the data of 1,095 patients who underwent curative lobar resection for NSCLC at Kanagawa Cancer Center. We divided patients into four groups according to sex and Brinkman index (BI) above or below 600. Six-month postoperative changes in the skeletal muscle index (SMI) were calculated and associations between clinicopathological factors including changes in SMI and mortality from postoperative 6 months were examined. Only in groups in which postoperative depletion of SMI was shown to be associated with the prognosis, we identified clinicopathological factors associated with depletive SMI.
RESULTS
RESULTS
The overall survival rates of 1,095 patients were 89.8% and 82.5% at 3 and 5 years, respectively. The median 6-month change in SMI was -3.4% (range, -22.3% to +17.9%). Multivariate analysis revealed that poor prognosis was independently predicted by a large reduction in the SMI (cut-off value: -10%) in males with a BI ≥600. In 391 heavy-smoking males, factors associated with a postoperative change in SMI ≤-10% were history of other cancers (including gastric cancer) low forced expiratory volume in one second (FEV 1.0, cut-off value: 1,870 mL), and prolonged operation time (cut-off value: 200 minutes).
CONCLUSIONS
CONCLUSIONS
Perioperative measures to prevent postoperative sarcopenia are appropriate for heavy smokers. We obtained some clues regarding countermeasures, one of which may be avoiding long-time operation. Further studies including clinical trials to assess perioperative anti-sarcopenia treatments, are needed.
Identifiants
pubmed: 32274097
doi: 10.21037/jtd.2020.01.44
pii: jtd-12-03-307
pmc: PMC7138994
doi:
Types de publication
Journal Article
Langues
eng
Pagination
307-318Informations de copyright
2020 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Ann Thorac Surg. 2019 Nov;108(5):1555-1564
pubmed: 31228408
J Thorac Oncol. 2014 Jun;9(6):812-7
pubmed: 24807154
Clin Cancer Res. 2009 Apr 15;15(8):2920-6
pubmed: 19351764
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Nutr Cancer. 2015;67(1):12-26
pubmed: 25513730
Am J Respir Crit Care Med. 1999 Dec;160(6):1856-61
pubmed: 10588597
Ann Surg Oncol. 2017 Jul;24(7):1795-1803
pubmed: 28213789
PLoS One. 2015 Oct 05;10(10):e0139749
pubmed: 26437072
Ann Surg Oncol. 2017 Nov;24(12):3741-3747
pubmed: 28861809
Int J Cardiol. 2002 Sep;85(1):101-10
pubmed: 12163214
J Thorac Dis. 2019 Aug;11(8):3411-3420
pubmed: 31559045
J Clin Oncol. 2010 Feb 20;28(6):1054-60
pubmed: 20085939
Clin Med Insights Oncol. 2015 Nov 09;9:87-93
pubmed: 26604850
Clin Nutr. 2012 Feb;31(1):74-7
pubmed: 21875767
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Lung Cancer. 2016 Nov;101:92-97
pubmed: 27794415
Ann Surg Oncol. 2018 May;25(5):1229-1236
pubmed: 29327178
Interact Cardiovasc Thorac Surg. 2019 Feb 1;28(2):235-239
pubmed: 30060057
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Am J Clin Nutr. 2010 Apr;91(4):1133S-1137S
pubmed: 20164322
Cancer Med. 2016 Apr;5(4):607-16
pubmed: 26814378
J Thorac Oncol. 2009 May;4(5):568-77
pubmed: 19357537
J Thorac Oncol. 2018 Jul;13(7):895-903
pubmed: 29751134
Clin Nutr. 2008 Dec;27(6):793-9
pubmed: 18718696
Eur J Surg Oncol. 2019 May;45(5):728-735
pubmed: 30348603
Eur J Radiol. 2018 Dec;109:142-146
pubmed: 30527297
Lung Cancer. 2015 Oct;90(1):85-91
pubmed: 26198373
Curr Opin Support Palliat Care. 2007 Dec;1(4):312-6
pubmed: 18685381
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):272-4
pubmed: 26675232
Ann Thorac Surg. 2007 Sep;84(3):946-50
pubmed: 17720404
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Eur J Cardiothorac Surg. 2014 Apr;45(4):660-4
pubmed: 24052607
J Thorac Dis. 2018 Sep;10(Suppl 26):S3138-S3142
pubmed: 30370098